Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Rhea-AI Summary
Humacyte (Nasdaq:HUMA) announced that its bioengineered vessel product Symvess is now under contract with the U.S. Department of Veterans Affairs’ Strategic Acquisition Center (SAC) through the Surgical Implant – Next Generation (SING) program.
This contract makes Symvess more easily accessible to 170 VA hospitals, SAC’s preferred sourcing sites, after SAC’s surgical committee product and value vetting. Symvess received FDA approval in December 2024 for extremity vascular trauma; for all other uses, it remains investigational and unapproved.
Positive
- SAC SING contract makes Symvess accessible to approximately 170 VA hospitals
- Symvess added to preferred and primary sourcing vehicle for VA hospitals
- Product passed SAC surgical committee product and value analysis requirements
- Symvess received FDA approval in December 2024 for extremity vascular trauma
Negative
- For indications beyond extremity vascular trauma, Symvess remains investigational and not FDA approved
- Symvess is not approved for sale by any non-U.S. regulatory agency
News Market Reaction – HUMA
In the May 20 session, HUMA gained 11.14%, reflecting a significant positive market reaction. Argus tracked a peak move of +20.9% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 15 | Clinical outcomes data | Positive | +4.1% | Published strong Symvess outcomes in 12 vascular complication patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For acquisition-tagged events, prior history shows a modest positive reaction (+4.08%), contrasting with today’s negative move.
In September 2025, HUMA’s only prior acquisition-tagged event involved publication of Symvess outcomes in 12 patients, showing 92% secondary patency at 23.3 months, 100% limb salvage, and no conduit infections. That update saw a +4.08% move. Today’s VA Strategic Acquisition Center contract similarly centers on expanding use of the FDA-approved Symvess vascular trauma product, but the share price reaction diverges from that earlier positive pattern.
Key Terms
food and drug administration (fda) regulatory
extremity vascular trauma medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals –
- SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals -
DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA). The SAC SING (Surgical Implant – Next Generation) contract makes Symvess more easily accessible to 170 VA hospitals as the SAC system is the preferred and primary sourcing vehicle for VA hospitals. SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals, making Symvess more readily available and visible across the entire VA system.
“We are pleased that Symvess is now under contract with the Strategic Acquisition Center, making the first-in-class product accessible to healthcare professionals treating military veterans,” said Dr. Laura Niklason, President and CEO of Humacyte, Inc. “SAC is the preferred sourcing vehicle for the VA, and we anticipate that the SAC SING contract will expedite our ability to respond to interest from surgeons operating in the VA system.”
Symvess (acellular tissue engineered vessel-tyod) was approved in the extremity vascular trauma indication by the Food and Drug Administration (FDA) in December 2024. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for use or sale by the FDA or any other regulatory agency.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing an innovative biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues designed to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize our ATEV in the United States under the brand name Symvess in vascular trauma repair; the statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials; the anticipated characteristics and performance of our ATEVs; the anticipated benefits of the ATEV relative to existing alternatives; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and the Form 10-Q for the quarter ended March 31, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
